Certolizumab pegol
Brand: Cimzia ®
NICE TA: 415
Indication: Rheumatoid arthritis, 2nd line after the failure of a TNF inhibitor (NICE TA415) and (LMMG RA Biologic Pathway)
Disease category: Musculoskeletal system
Commissioning responsibility: CCG
PbR excluded: Yes
Background
Treatment to be continued with the most cost effective, clinically appropriate drug (taking into account administration costs, required dose and product price per dose). This may need to be varied in individual cases due to differences in the mode of administration and treatment schedules.
Recommendation
LMMG recommendation: Red
Click here to find the definitions for the colour classifications
Reason for decision: Specialist medicine
Supporting documents:
Rheumatoid Arthritis Pathway (Version 3.0) (101.4 KiB)
Decisions of Lancashire local decision making groups:
NHS Blackburn With Darwen CCG and NHS East Lancashire CCG | NHS Blackpool CCG | NHS Chorley and South Ribble CCG and NHS Greater Preston CCG | NHS Fylde and Wyre CCG | NHS Morecambe Bay CCG | NHS West Lancashire CCG |
---|---|---|---|---|---|
Red |
Red |
Red |
Red |
Red |
Red |